Masitinib mesylate is the orally bioavailable mesylate salt of masitinib, a multi-targeted protein tyrosine kinase inhibitor. It selectively binds to and inhibits several receptor tyrosine kinases, including wild-type and mutated forms of c-Kit, PDGFR, and FGFR3, thereby potentially inhibiting tumor cell proliferation.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1048007-93-7
(3S,4S)-3-hexyl-4-((R)-2-hydroxytridecyl)-2-oxetanone
pharmaceutical raw material
(+)-geosmin
pharmaceutical raw material
2-(tert-Butylamino)-3'-bromopropiophenone Hydrochloride
pharmaceutical raw material
2-(tert-butylamino)-1-(4-chlorophenyl)propan-1-one hydrochloride
pharmaceutical raw material
methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide
TXCWBWKVIZGWEQ-UHFFFAOYSA-N
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5.CS(=O)(=O)O